nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.0106	0.0106	CcSEcCtD
Nebivolol—Abdominal pain—Valrubicin—urinary bladder cancer	0.0102	0.0102	CcSEcCtD
Nebivolol—Syncope—Mitomycin—urinary bladder cancer	0.00981	0.00981	CcSEcCtD
Nebivolol—Loss of consciousness—Mitomycin—urinary bladder cancer	0.00961	0.00961	CcSEcCtD
Nebivolol—Asthenia—Valrubicin—urinary bladder cancer	0.0093	0.0093	CcSEcCtD
Nebivolol—Pruritus—Valrubicin—urinary bladder cancer	0.00917	0.00917	CcSEcCtD
Nebivolol—Diarrhoea—Valrubicin—urinary bladder cancer	0.00886	0.00886	CcSEcCtD
Nebivolol—Shock—Mitomycin—urinary bladder cancer	0.00878	0.00878	CcSEcCtD
Nebivolol—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00874	0.00874	CcSEcCtD
Nebivolol—Psoriasis—Methotrexate—urinary bladder cancer	0.00861	0.00861	CcSEcCtD
Nebivolol—Dizziness—Valrubicin—urinary bladder cancer	0.00857	0.00857	CcSEcCtD
Nebivolol—Vomiting—Valrubicin—urinary bladder cancer	0.00824	0.00824	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Thiotepa—urinary bladder cancer	0.00822	0.00822	CcSEcCtD
Nebivolol—Rash—Valrubicin—urinary bladder cancer	0.00817	0.00817	CcSEcCtD
Nebivolol—Dermatitis—Valrubicin—urinary bladder cancer	0.00816	0.00816	CcSEcCtD
Nebivolol—Headache—Valrubicin—urinary bladder cancer	0.00812	0.00812	CcSEcCtD
Nebivolol—Psoriasis—Epirubicin—urinary bladder cancer	0.00806	0.00806	CcSEcCtD
Nebivolol—Dyspnoea—Mitomycin—urinary bladder cancer	0.00796	0.00796	CcSEcCtD
Nebivolol—Somnolence—Mitomycin—urinary bladder cancer	0.00793	0.00793	CcSEcCtD
Nebivolol—Renal failure acute—Cisplatin—urinary bladder cancer	0.00776	0.00776	CcSEcCtD
Nebivolol—Nausea—Valrubicin—urinary bladder cancer	0.0077	0.0077	CcSEcCtD
Nebivolol—Fatigue—Mitomycin—urinary bladder cancer	0.0077	0.0077	CcSEcCtD
Nebivolol—Psoriasis—Doxorubicin—urinary bladder cancer	0.00746	0.00746	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Gemcitabine—urinary bladder cancer	0.00692	0.00692	CcSEcCtD
Nebivolol—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00653	0.00653	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Cisplatin—urinary bladder cancer	0.00645	0.00645	CcSEcCtD
Nebivolol—Asthenia—Mitomycin—urinary bladder cancer	0.0064	0.0064	CcSEcCtD
Nebivolol—Diarrhoea—Mitomycin—urinary bladder cancer	0.00611	0.00611	CcSEcCtD
Nebivolol—Dizziness—Mitomycin—urinary bladder cancer	0.0059	0.0059	CcSEcCtD
Nebivolol—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00586	0.00586	CcSEcCtD
Nebivolol—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.00584	0.00584	CcSEcCtD
Nebivolol—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.0058	0.0058	CcSEcCtD
Nebivolol—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.00574	0.00574	CcSEcCtD
Nebivolol—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.00571	0.00571	CcSEcCtD
Nebivolol—Vomiting—Mitomycin—urinary bladder cancer	0.00567	0.00567	CcSEcCtD
Nebivolol—Rash—Mitomycin—urinary bladder cancer	0.00563	0.00563	CcSEcCtD
Nebivolol—Dermatitis—Mitomycin—urinary bladder cancer	0.00562	0.00562	CcSEcCtD
Nebivolol—Headache—Mitomycin—urinary bladder cancer	0.00559	0.00559	CcSEcCtD
Nebivolol—Bronchospasm—Etoposide—urinary bladder cancer	0.00558	0.00558	CcSEcCtD
Nebivolol—Mental disorder—Thiotepa—urinary bladder cancer	0.00554	0.00554	CcSEcCtD
Nebivolol—Malnutrition—Thiotepa—urinary bladder cancer	0.0055	0.0055	CcSEcCtD
Nebivolol—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.00544	0.00544	CcSEcCtD
Nebivolol—Myocardial infarction—Cisplatin—urinary bladder cancer	0.00541	0.00541	CcSEcCtD
Nebivolol—Nausea—Mitomycin—urinary bladder cancer	0.0053	0.0053	CcSEcCtD
Nebivolol—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.00524	0.00524	CcSEcCtD
Nebivolol—Atrioventricular block—Epirubicin—urinary bladder cancer	0.00522	0.00522	CcSEcCtD
Nebivolol—Bradycardia—Cisplatin—urinary bladder cancer	0.00504	0.00504	CcSEcCtD
Nebivolol—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.00498	0.00498	CcSEcCtD
Nebivolol—Myocardial infarction—Etoposide—urinary bladder cancer	0.00496	0.00496	CcSEcCtD
Nebivolol—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00493	0.00493	CcSEcCtD
Nebivolol—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.00483	0.00483	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00465	0.00465	CcSEcCtD
Nebivolol—Cardiac disorder—Cisplatin—urinary bladder cancer	0.0046	0.0046	CcSEcCtD
Nebivolol—Nervous system disorder—Thiotepa—urinary bladder cancer	0.0044	0.0044	CcSEcCtD
Nebivolol—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00439	0.00439	CcSEcCtD
Nebivolol—Skin disorder—Thiotepa—urinary bladder cancer	0.00436	0.00436	CcSEcCtD
Nebivolol—Malnutrition—Cisplatin—urinary bladder cancer	0.00431	0.00431	CcSEcCtD
Nebivolol—Renal failure acute—Methotrexate—urinary bladder cancer	0.00426	0.00426	CcSEcCtD
Nebivolol—Cardiac disorder—Etoposide—urinary bladder cancer	0.00421	0.00421	CcSEcCtD
Nebivolol—Paraesthesia—Thiotepa—urinary bladder cancer	0.00403	0.00403	CcSEcCtD
Nebivolol—Somnolence—Thiotepa—urinary bladder cancer	0.00399	0.00399	CcSEcCtD
Nebivolol—Renal failure acute—Epirubicin—urinary bladder cancer	0.00398	0.00398	CcSEcCtD
Nebivolol—Chest pain—Gemcitabine—urinary bladder cancer	0.00394	0.00394	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00391	0.00391	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00388	0.00388	CcSEcCtD
Nebivolol—Chest pain—Fluorouracil—urinary bladder cancer	0.00387	0.00387	CcSEcCtD
Nebivolol—Fatigue—Thiotepa—urinary bladder cancer	0.00387	0.00387	CcSEcCtD
Nebivolol—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.0037	0.0037	CcSEcCtD
Nebivolol—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.0037	0.0037	CcSEcCtD
Nebivolol—Renal failure acute—Doxorubicin—urinary bladder cancer	0.00369	0.00369	CcSEcCtD
Nebivolol—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00367	0.00367	CcSEcCtD
Nebivolol—Skin disorder—Gemcitabine—urinary bladder cancer	0.00367	0.00367	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00365	0.00365	CcSEcCtD
Nebivolol—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00364	0.00364	CcSEcCtD
Nebivolol—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00363	0.00363	CcSEcCtD
Nebivolol—Urticaria—Thiotepa—urinary bladder cancer	0.00357	0.00357	CcSEcCtD
Nebivolol—Vertigo—Etoposide—urinary bladder cancer	0.00355	0.00355	CcSEcCtD
Nebivolol—Abdominal pain—Thiotepa—urinary bladder cancer	0.00355	0.00355	CcSEcCtD
Nebivolol—Loss of consciousness—Etoposide—urinary bladder cancer	0.00347	0.00347	CcSEcCtD
Nebivolol—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00345	0.00345	CcSEcCtD
Nebivolol—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00345	0.00345	CcSEcCtD
Nebivolol—Skin disorder—Cisplatin—urinary bladder cancer	0.00342	0.00342	CcSEcCtD
Nebivolol—Insomnia—Gemcitabine—urinary bladder cancer	0.00342	0.00342	CcSEcCtD
Nebivolol—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00339	0.00339	CcSEcCtD
Nebivolol—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00337	0.00337	CcSEcCtD
Nebivolol—Chest pain—Etoposide—urinary bladder cancer	0.00336	0.00336	CcSEcCtD
Nebivolol—Insomnia—Fluorouracil—urinary bladder cancer	0.00336	0.00336	CcSEcCtD
Nebivolol—Somnolence—Gemcitabine—urinary bladder cancer	0.00336	0.00336	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00334	0.00334	CcSEcCtD
Nebivolol—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00333	0.00333	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Nebivolol—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Nebivolol—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Nebivolol—Somnolence—Fluorouracil—urinary bladder cancer	0.0033	0.0033	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Nebivolol—Fatigue—Gemcitabine—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Nebivolol—Asthenia—Thiotepa—urinary bladder cancer	0.00322	0.00322	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00321	0.00321	CcSEcCtD
Nebivolol—Pruritus—Thiotepa—urinary bladder cancer	0.00318	0.00318	CcSEcCtD
Nebivolol—Paraesthesia—Cisplatin—urinary bladder cancer	0.00316	0.00316	CcSEcCtD
Nebivolol—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00316	0.00316	CcSEcCtD
Nebivolol—Dyspnoea—Cisplatin—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Nebivolol—Skin disorder—Etoposide—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Nebivolol—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Nebivolol—Diarrhoea—Thiotepa—urinary bladder cancer	0.00307	0.00307	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00304	0.00304	CcSEcCtD
Nebivolol—Dizziness—Thiotepa—urinary bladder cancer	0.00297	0.00297	CcSEcCtD
Nebivolol—Urticaria—Fluorouracil—urinary bladder cancer	0.00295	0.00295	CcSEcCtD
Nebivolol—Paraesthesia—Etoposide—urinary bladder cancer	0.0029	0.0029	CcSEcCtD
Nebivolol—Dyspnoea—Etoposide—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Nebivolol—Somnolence—Etoposide—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Nebivolol—Vomiting—Thiotepa—urinary bladder cancer	0.00285	0.00285	CcSEcCtD
Nebivolol—Rash—Thiotepa—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Nebivolol—Dermatitis—Thiotepa—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Nebivolol—Headache—Thiotepa—urinary bladder cancer	0.00281	0.00281	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00278	0.00278	CcSEcCtD
Nebivolol—Fatigue—Etoposide—urinary bladder cancer	0.00278	0.00278	CcSEcCtD
Nebivolol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Nebivolol—Asthenia—Gemcitabine—urinary bladder cancer	0.00271	0.00271	CcSEcCtD
Nebivolol—Pruritus—Gemcitabine—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Nebivolol—Nausea—Thiotepa—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Nebivolol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Nebivolol—Pruritus—Fluorouracil—urinary bladder cancer	0.00263	0.00263	CcSEcCtD
Nebivolol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Nebivolol—Bradycardia—Epirubicin—urinary bladder cancer	0.00259	0.00259	CcSEcCtD
Nebivolol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00258	0.00258	CcSEcCtD
Nebivolol—Urticaria—Etoposide—urinary bladder cancer	0.00256	0.00256	CcSEcCtD
Nebivolol—Abdominal pain—Etoposide—urinary bladder cancer	0.00255	0.00255	CcSEcCtD
Nebivolol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Nebivolol—Asthenia—Cisplatin—urinary bladder cancer	0.00253	0.00253	CcSEcCtD
Nebivolol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00252	0.00252	CcSEcCtD
Nebivolol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Nebivolol—Dizziness—Fluorouracil—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Nebivolol—Diarrhoea—Cisplatin—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Nebivolol—Vomiting—Gemcitabine—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Nebivolol—Bradycardia—Doxorubicin—urinary bladder cancer	0.0024	0.0024	CcSEcCtD
Nebivolol—Mental disorder—Methotrexate—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Nebivolol—Rash—Gemcitabine—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Nebivolol—Dermatitis—Gemcitabine—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Nebivolol—Hypersensitivity—Etoposide—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Nebivolol—Malnutrition—Methotrexate—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Nebivolol—Headache—Gemcitabine—urinary bladder cancer	0.00237	0.00237	CcSEcCtD
Nebivolol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00236	0.00236	CcSEcCtD
Nebivolol—Vomiting—Fluorouracil—urinary bladder cancer	0.00236	0.00236	CcSEcCtD
Nebivolol—Rash—Fluorouracil—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Nebivolol—Dermatitis—Fluorouracil—urinary bladder cancer	0.00234	0.00234	CcSEcCtD
Nebivolol—Headache—Fluorouracil—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Nebivolol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Nebivolol—Asthenia—Etoposide—urinary bladder cancer	0.00231	0.00231	CcSEcCtD
Nebivolol—Pruritus—Etoposide—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Nebivolol—Nausea—Gemcitabine—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Nebivolol—Vomiting—Cisplatin—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Nebivolol—Mental disorder—Epirubicin—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Nebivolol—Rash—Cisplatin—urinary bladder cancer	0.00222	0.00222	CcSEcCtD
Nebivolol—Dermatitis—Cisplatin—urinary bladder cancer	0.00222	0.00222	CcSEcCtD
Nebivolol—Malnutrition—Epirubicin—urinary bladder cancer	0.00221	0.00221	CcSEcCtD
Nebivolol—Diarrhoea—Etoposide—urinary bladder cancer	0.00221	0.00221	CcSEcCtD
Nebivolol—Nausea—Fluorouracil—urinary bladder cancer	0.00221	0.00221	CcSEcCtD
Nebivolol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00218	0.00218	CcSEcCtD
Nebivolol—Dizziness—Etoposide—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Nebivolol—Vertigo—Methotrexate—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Nebivolol—Nausea—Cisplatin—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Nebivolol—Mental disorder—Doxorubicin—urinary bladder cancer	0.00206	0.00206	CcSEcCtD
Nebivolol—Vomiting—Etoposide—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Nebivolol—Malnutrition—Doxorubicin—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Nebivolol—Rash—Etoposide—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Nebivolol—Dermatitis—Etoposide—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Nebivolol—Headache—Etoposide—urinary bladder cancer	0.00202	0.00202	CcSEcCtD
Nebivolol—Chest pain—Methotrexate—urinary bladder cancer	0.00201	0.00201	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.002	0.002	CcSEcCtD
Nebivolol—Vertigo—Epirubicin—urinary bladder cancer	0.00199	0.00199	CcSEcCtD
Nebivolol—Syncope—Epirubicin—urinary bladder cancer	0.00199	0.00199	CcSEcCtD
Nebivolol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Nebivolol—Nausea—Etoposide—urinary bladder cancer	0.00192	0.00192	CcSEcCtD
Nebivolol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Nebivolol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Nebivolol—Chest pain—Epirubicin—urinary bladder cancer	0.00189	0.00189	CcSEcCtD
Nebivolol—Skin disorder—Methotrexate—urinary bladder cancer	0.00188	0.00188	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Nebivolol—Vertigo—Doxorubicin—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Nebivolol—Syncope—Doxorubicin—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Nebivolol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.0018	0.0018	CcSEcCtD
Nebivolol—Shock—Epirubicin—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Nebivolol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00177	0.00177	CcSEcCtD
Nebivolol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00177	0.00177	CcSEcCtD
Nebivolol—Skin disorder—Epirubicin—urinary bladder cancer	0.00176	0.00176	CcSEcCtD
Nebivolol—Insomnia—Methotrexate—urinary bladder cancer	0.00175	0.00175	CcSEcCtD
Nebivolol—Chest pain—Doxorubicin—urinary bladder cancer	0.00174	0.00174	CcSEcCtD
Nebivolol—Paraesthesia—Methotrexate—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00173	0.00173	CcSEcCtD
Nebivolol—Dyspnoea—Methotrexate—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Nebivolol—Somnolence—Methotrexate—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Nebivolol—Fatigue—Methotrexate—urinary bladder cancer	0.00167	0.00167	CcSEcCtD
Nebivolol—Shock—Doxorubicin—urinary bladder cancer	0.00165	0.00165	CcSEcCtD
Nebivolol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Nebivolol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Nebivolol—Insomnia—Epirubicin—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Nebivolol—Skin disorder—Doxorubicin—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Nebivolol—Paraesthesia—Epirubicin—urinary bladder cancer	0.00162	0.00162	CcSEcCtD
Nebivolol—Dyspnoea—Epirubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Nebivolol—Somnolence—Epirubicin—urinary bladder cancer	0.00161	0.00161	CcSEcCtD
Nebivolol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00158	0.00158	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Nebivolol—Fatigue—Epirubicin—urinary bladder cancer	0.00156	0.00156	CcSEcCtD
Nebivolol—Urticaria—Methotrexate—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Nebivolol—Abdominal pain—Methotrexate—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Nebivolol—Insomnia—Doxorubicin—urinary bladder cancer	0.00151	0.00151	CcSEcCtD
Nebivolol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.0015	0.0015	CcSEcCtD
Nebivolol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Nebivolol—Somnolence—Doxorubicin—urinary bladder cancer	0.00149	0.00149	CcSEcCtD
Nebivolol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Nebivolol—Fatigue—Doxorubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Nebivolol—Urticaria—Epirubicin—urinary bladder cancer	0.00144	0.00144	CcSEcCtD
Nebivolol—Abdominal pain—Epirubicin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Nebivolol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00142	0.00142	CcSEcCtD
Nebivolol—Asthenia—Methotrexate—urinary bladder cancer	0.00139	0.00139	CcSEcCtD
Nebivolol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Nebivolol—Pruritus—Methotrexate—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Nebivolol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00133	0.00133	CcSEcCtD
Nebivolol—Urticaria—Doxorubicin—urinary bladder cancer	0.00133	0.00133	CcSEcCtD
Nebivolol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Nebivolol—Diarrhoea—Methotrexate—urinary bladder cancer	0.00132	0.00132	CcSEcCtD
Nebivolol—Asthenia—Epirubicin—urinary bladder cancer	0.0013	0.0013	CcSEcCtD
Nebivolol—Pruritus—Epirubicin—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Nebivolol—Dizziness—Methotrexate—urinary bladder cancer	0.00128	0.00128	CcSEcCtD
Nebivolol—Diarrhoea—Epirubicin—urinary bladder cancer	0.00124	0.00124	CcSEcCtD
Nebivolol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Nebivolol—Vomiting—Methotrexate—urinary bladder cancer	0.00123	0.00123	CcSEcCtD
Nebivolol—Rash—Methotrexate—urinary bladder cancer	0.00122	0.00122	CcSEcCtD
Nebivolol—Dermatitis—Methotrexate—urinary bladder cancer	0.00122	0.00122	CcSEcCtD
Nebivolol—Headache—Methotrexate—urinary bladder cancer	0.00121	0.00121	CcSEcCtD
Nebivolol—Asthenia—Doxorubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Nebivolol—Dizziness—Epirubicin—urinary bladder cancer	0.0012	0.0012	CcSEcCtD
Nebivolol—Pruritus—Doxorubicin—urinary bladder cancer	0.00118	0.00118	CcSEcCtD
Nebivolol—Vomiting—Epirubicin—urinary bladder cancer	0.00115	0.00115	CcSEcCtD
Nebivolol—Nausea—Methotrexate—urinary bladder cancer	0.00115	0.00115	CcSEcCtD
Nebivolol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Nebivolol—Rash—Epirubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Nebivolol—Dermatitis—Epirubicin—urinary bladder cancer	0.00114	0.00114	CcSEcCtD
Nebivolol—Headache—Epirubicin—urinary bladder cancer	0.00113	0.00113	CcSEcCtD
Nebivolol—Dizziness—Doxorubicin—urinary bladder cancer	0.00111	0.00111	CcSEcCtD
Nebivolol—Nausea—Epirubicin—urinary bladder cancer	0.00107	0.00107	CcSEcCtD
Nebivolol—Vomiting—Doxorubicin—urinary bladder cancer	0.00106	0.00106	CcSEcCtD
Nebivolol—Rash—Doxorubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Nebivolol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Nebivolol—Headache—Doxorubicin—urinary bladder cancer	0.00105	0.00105	CcSEcCtD
Nebivolol—Nausea—Doxorubicin—urinary bladder cancer	0.000993	0.000993	CcSEcCtD
